期刊文献+

血管生成素在淀粉样沉积症中发挥作用吗?(英文)

Does Angiogenin Play a Role in Amyloid Diseases?
下载PDF
导出
摘要 淀粉样沉积症是致命性的疾病,可以是神经退行性的,也可以是系统性的.该疾病以错误折叠蛋白质的堆积、缠绕成纤维为特征,最终导致受累组织、器官的渐进性坏死.目前,没有有效的治疗手段可以阻止该类疾病的进程.错误折叠蛋白质的累积诱导内质网应激,被认为是退行性疾病的标志.血管生成素不仅可以调节细胞生长和增殖,也在应激条件下细胞存活中发挥作用.最近,发现血管生成素介导的应激反应可以减轻蛋白聚积造成的损伤,提示该蛋白可能在退行性疾病中具有新功能.本综述概述了血管生成素在淀粉样沉积症中的研究进展,特别是描述了血管生成素失调与该类疾病的起始和进展间的关系.我们认为,深入了解血管生成素失调的分子基础有助于发展与蛋白质错误折叠和聚积相关的退行性疾病的治疗方法. Amyloidoses are the devastating diseases, either neurodegenerative or systemic (targeted to peripheral organs), characterized by accumulation and aggregation of misfolded proteins into fibrils, finally leading to a progressive failure of affected tissues and organs. To date, no therapeutic approaches are available to counteract the progression of this class of diseases. Accumulation of misfolded protein aggregates increases endoplasmic reticulum stress, which can be considered a hallmark of degenerative diseases. Angiogenin, which is known to regulate cell growth and proliferation, plays a key role in sustaining cell survival under stress conditions. Recently, a new role for angiogenin in degenerative diseases is emerged, since stress response mediated by angiogenin is believed to alleviate damages inflicted by protein aggregates. This review reports some of the issues providing support to the role of angiogenin in amyloidoses and we described the recent advances toward the elucidation of the correlation between angiogenin deregulation and the onset/progression of the pathology. A detailed understanding of the molecular basis of angiogenin deregulation might lead to the development of therapies for degenerative disorders that are associated with protein misfolding and aggregation.
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2015年第12期1276-1283,共8页 Chinese Journal of Biochemistry and Molecular Biology
关键词 血管生成素 神经退行性疾病 系统性淀粉样沉积症 angiogenin neurodegeneration systemic amyloidosis
  • 相关文献

参考文献69

  • 1Chiti F, Dobson C M. Protein misfolding, functional amyloid, and human disease [J]. Annu Rev Biochem, 2006, 75: 333-366.
  • 2Sipe J D, Benson M D, Buxbaum J N, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis [J]. Amyloid, 2014, 21(4): 221-224.
  • 3Relini A, Rolandi R, Bolognesi M, et al. Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study [J]. Biochim Biophys Acta, 2004, 1690(1): 33-41.
  • 4Ferreira S T, De Felice F G, Chapeaurouge A. Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins [J]. Cell Biochem Biophys, 2006, 44(3): 539-548.
  • 5Westermark P, Benson M D, Buxbaum J N, et al. A primer of amyloid nomenclature [J]. Amyloid, 2007, 14(3): 179-183.
  • 6Ferreira S T, Vieira M N, De Felice F G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases [J]. IUBMB Life, 2007, 59(4-5): 332-345.
  • 7Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world [J]. Biochim Biophys Acta, 2004, 1739(1): 5-25.
  • 8Stefani M, Dobson C M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution [J]. J Mol Med (Berl), 2003, 81(11): 678-699.
  • 9Westermark P, Benson M D, Buxbaum J N, et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis [J]. Amyloid, 2005, 12(1): 1-4.
  • 10Agorogiannis E I, Agorogiannis G I, Papadimitriou A, et al. Protein misfolding in neurodegenerative diseases [J]. Neuropathol Appl Neurobiol, 2004, 30(3): 215-224.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部